

15th January, 2024

Dear REMAP-CAP site investigators and research staff,

RE: REMAP-CAP Cysteamine Domain

We are writing to inform you of a decision that has been made by the REMAP-CAP International Trial Steering Committee (ITSC) and Cysteamine Domain-Specific Working Group (DSWG) to close recruitment to the Cysteamine Domain of REMAP-CAP.

Due to declining case numbers of patients with COVID-19 and limited site participation, recruitment to this domain is less than we had anticipated. Further, the current batch of Cysteamine IMP expired on the 23rd December 2023 and the company have decided not to continue to support the domain, in light of recruitment over the last 12 months. It was therefore considered that continuation of this domain is operationally futile.

We recommend that for participants who have been allocated to an intervention within this domain, administration of allocated interventions should be continued as per the Cysteamine Domain-Specific Appendix.

We thank you sincerely for your participation in the Cysteamine Domain, and REMAP-CAP overall, as we continue to evaluate optimal treatment for CAP and COVID-19. We look forward to sharing the results of this domain with you, and the public, as soon as they are available.

Sincerely,



Srinivas Murthy
Chair, REMAP-CAP ITSC



Manu Shankar-Hari
Chair, Cysteamine DSWG